Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations

Breadcrumb

  1. Emmes Group

Clinical trials referral resource. Current cooperative group phase III clinical trials in early-stage breast cancer.

Go back to Resources

Clinical trials referral resource. Current cooperative group phase III clinical trials in early-stage breast cancer.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

Keywords:

Go back to Resources

Health-Related Quality of Life in children with autism spectrum disorders: results from the autism treatment network.

Go back to Resources

Health-Related Quality of Life in children with autism spectrum disorders: results from the autism treatment network.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Genome-wide association identifies SKIV2L and MYRIP as protective factors for age-related macular degeneration.

Go back to Resources

Genome-wide association identifies SKIV2L and MYRIP as protective factors for age-related macular degeneration.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.

Go back to Resources

A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Variables affecting estimated glomerular filtration rate after renal transplantation in children: a NAPRTCS data analysis.

Go back to Resources

Variables affecting estimated glomerular filtration rate after renal transplantation in children: a NAPRTCS data analysis.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Specifying methods for mean VA calculations.

Go back to Resources

Specifying methods for mean VA calculations.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Go back to Resources

Seroprevalence of cytomegalovirus (CMV) and risk factors for infection in adolescent males.

Go back to Resources

Seroprevalence of cytomegalovirus (CMV) and risk factors for infection in adolescent males.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

SCORE Study Report 8: Closed Tests for All Pair-Wise Comparisons of Means.

Go back to Resources

SCORE Study Report 8: Closed Tests for All Pair-Wise Comparisons of Means.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Abstract:

Go back to Resources

Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.

Go back to Resources

Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.

Go back to Resources

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 60
  • Page 61
  • Page 62
  • Page 63
  • Current page 64
  • Page 65
  • Page 66
  • Page 67
  • Page 68
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • Terms of Use
  • ISO Certification